Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer

Multidrug resistance (MDR) is a major obstacle to successful cancer treatment and is crucial to cancer metastasis and relapse. Combination therapy is an effective strategy for overcoming MDR. However, the different pharmacokinetic (PK) profiles of combined drugs often undermine the combination effec...

Full description

Bibliographic Details
Main Authors: Meng Zhang, Ergang Liu, Yanna Cui, Yongzhuo Huang
Format: Article
Language:English
Published: China Anti-Cancer Association 2017-06-01
Series:Cancer Biology & Medicine
Subjects:
Online Access:http://www.cancerbiomed.org/index.php/cocr/article/view/1044
id doaj-076afec336cb422cbf6d13cadb52999d
record_format Article
spelling doaj-076afec336cb422cbf6d13cadb52999d2020-11-25T02:03:26ZengChina Anti-Cancer AssociationCancer Biology & Medicine2095-39412095-39412017-06-0114321222710.20892/j.issn.2095-3941.2017.00542017000054Nanotechnology-based combination therapy for overcoming multidrug-resistant cancerMeng Zhang0Ergang Liu1Yanna Cui2Yongzhuo Huang3Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China;Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China;Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China;Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China;Multidrug resistance (MDR) is a major obstacle to successful cancer treatment and is crucial to cancer metastasis and relapse. Combination therapy is an effective strategy for overcoming MDR. However, the different pharmacokinetic (PK) profiles of combined drugs often undermine the combination effect <i>in vivo</i>, especially when greatly different physicochemical properties (e.g., those of macromolecules and small drugs) combine. To address this issue, nanotechnology-based codelivery techniques have been actively explored. They possess great advantages for tumor targeting, controlled drug release, and identical drug PK profiles. Thus, a powerful tool for combination therapy is provided, and the translation from <i>in vitro</i> to <i>in vivo</i> is facilitated. In this review, we present a summary of various combination strategies for overcoming MDR and the nanotechnology-based combination therapy.http://www.cancerbiomed.org/index.php/cocr/article/view/1044Drug deliverynanotechnologymultidrug resistancecombination therapycancer therapy
collection DOAJ
language English
format Article
sources DOAJ
author Meng Zhang
Ergang Liu
Yanna Cui
Yongzhuo Huang
spellingShingle Meng Zhang
Ergang Liu
Yanna Cui
Yongzhuo Huang
Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer
Cancer Biology & Medicine
Drug delivery
nanotechnology
multidrug resistance
combination therapy
cancer therapy
author_facet Meng Zhang
Ergang Liu
Yanna Cui
Yongzhuo Huang
author_sort Meng Zhang
title Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer
title_short Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer
title_full Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer
title_fullStr Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer
title_full_unstemmed Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer
title_sort nanotechnology-based combination therapy for overcoming multidrug-resistant cancer
publisher China Anti-Cancer Association
series Cancer Biology & Medicine
issn 2095-3941
2095-3941
publishDate 2017-06-01
description Multidrug resistance (MDR) is a major obstacle to successful cancer treatment and is crucial to cancer metastasis and relapse. Combination therapy is an effective strategy for overcoming MDR. However, the different pharmacokinetic (PK) profiles of combined drugs often undermine the combination effect <i>in vivo</i>, especially when greatly different physicochemical properties (e.g., those of macromolecules and small drugs) combine. To address this issue, nanotechnology-based codelivery techniques have been actively explored. They possess great advantages for tumor targeting, controlled drug release, and identical drug PK profiles. Thus, a powerful tool for combination therapy is provided, and the translation from <i>in vitro</i> to <i>in vivo</i> is facilitated. In this review, we present a summary of various combination strategies for overcoming MDR and the nanotechnology-based combination therapy.
topic Drug delivery
nanotechnology
multidrug resistance
combination therapy
cancer therapy
url http://www.cancerbiomed.org/index.php/cocr/article/view/1044
work_keys_str_mv AT mengzhang nanotechnologybasedcombinationtherapyforovercomingmultidrugresistantcancer
AT ergangliu nanotechnologybasedcombinationtherapyforovercomingmultidrugresistantcancer
AT yannacui nanotechnologybasedcombinationtherapyforovercomingmultidrugresistantcancer
AT yongzhuohuang nanotechnologybasedcombinationtherapyforovercomingmultidrugresistantcancer
_version_ 1724948328277344256